Ranibizumab is a recombinant humanized IgG1 monoclonal antibody fragment that binds to and inhibits vascular endothelial growth factor A
Merck KGaA, Darmstadt, Germany announced the presentation of new oncology data across more than 12 tumor types at ASCO 2025
AstraZeneca and Daiichi Sankyo’s Enhertu followed by THP showed an improved safety profile vs. standard of care
IGI recently completed the dose-escalation portion of its Phase 1 clinical study in patients with heavily pretreated multiple myeloma
Merck Wilmington Biotech will serve as a launch and commercial production facility and the future U.S. home for KEYTRUDA
The company has received final approval from the Department of Pharmaceuticals, Government of India, for foreign investment under applicable regulations
Multiple studies show the combination potential of vedotin antibody-drug conjugates (ADCs) with pembrolizumab, including the first Phase 1 data in thoracic cancers for two first-in-class ADCs
Blenrep combinations could redefine treatment as early as first relapse where more effective options are needed
Jobevne is a vascular endothelial growth factor (VEGF) inhibitor that binds with VEGF and blocks the interaction with its receptors to prevent angiogenesis
Asahi Kasei Life Science covers a broad range of bioprocess products and services
Subscribe To Our Newsletter & Stay Updated
